theasialive3h
Blackstone’s Strategic Move in Japan’s Pharmaceutical Sector: A Game-Changer for Clinical Trials
In a significant move that underscores the growing interest of global private equity firms in Japan’s life sciences industry, ...
Bain Capital Specialty Finance: Q4 Results Show NAV Growth & Strong Dividend Coverage
Bain Capital Specialty Finance’s strong earnings and defensive portfolio make it attractive. See why BCSF stock, with high ...
PE Hub9h
Bain & Co’s Schmitz expects plenty of dealmaking opportunities; Blackstone, Permira-backed Adevinta sells Austrian digital marketplace
Adevinta is backed by Blackstone and Permira. The duo acquired the Norwegian online marketplace group in 2024 in a deal ...
PE Hub14h
Bain & Co: Dealmaking has ‘turned the corner,’ despite slow January
Bain & Co is “mildly optimistic” about private equity dealmaking in 2025, with a lot of processes being prepared and many ...
Dealmaking rebound sees private equity recovery taking shape -- Bain & Company Global PE Report
A global private equity (PE) revival is taking shape with a rebound in dealmaking gaining traction. But lingering headwinds ...
Business Times14h
Blackstone buys Japan drug trial firm, adding to private equity health deals
BLACKSTONE is buying a company that helps drugmakers run clinical trials in Japan, adding to growing interest from private ...
Blackstone Buys Japan Drug Trial Firm, Adding to PE Health Deals
Blackstone Inc. is buying a company that helps drugmakers run clinical trials in Japan, adding to growing interest from private equity firms in the health needs of the nation’s aging population. Most ...
HMC Capital must lift its offer to lenders to secure Healthscope
David Di Pilla’s HMC Capital may need to pay 40c in the dollar or $640m to Healthscope’s lenders, who are owed $1.6bn, to ...